Aptevo Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 7.95 million compared to net income of USD 28.01 million a year ago. Basic loss per share from continuing operations was USD 54.1199 compared to basic earnings per share from continuing operations of USD 244.1997 a year ago. Diluted loss per share from continuing operations was USD 54.1199 compared to diluted earnings per share from continuing operations of USD 244.1997 a year ago. Basic loss per share was USD 54.1199 compared to basic earnings per share of USD 245.5197 a year ago. Diluted loss per share was USD 54.1199 compared to diluted earnings per share of USD 245.5197 a year ago.
For the six months, net loss was USD 5.18 million compared to net income of USD 20.31 million a year ago. Basic loss per share from continuing operations was USD 37.4 compared to basic earnings per share from continuing operations of USD 176.4398 a year ago. Diluted loss per share from continuing operations was USD 37.4 compared to diluted earnings per share from continuing operations of USD 176.4398 a year ago. Basic loss per share was USD 31.68 compared to basic earnings per share of USD 179.5198 a year ago. Diluted loss per share was USD 31.68 compared to diluted earnings per share of USD 179.5198 a year ago.